Pathologic Lymph Node Staging of Gastric Cancer
Cristina Díaz Del Arco1,2, Luis Ortega Medina1,2, Lourdes Estrada Muñoz3
1Department of Surgical Pathology, Hospital Clínico San Carlos, Madrid, Spain.
American Journal of Clinical Pathology
|July 17, 2021
Summary
Assessing lymph nodes (LNs) in gastric cancer (GC) presents challenges. While the TNM system is standard, alternative methods and features like extracapsular extension show promise for improved staging and patient outcomes.
Area of Science:
- Oncology
- Surgical Pathology
- Cancer Staging
Background:
- Lymph node (LN) staging is critical in gastric cancer (GC) management.
- The current TNM classification relies primarily on the number of metastatic LNs.
- Emerging research explores alternative staging systems and additional pathological features.
Purpose of the Study:
- To review the challenges in lymph node assessment for gastric cancer.
- To discuss alternative lymph node staging systems and novel prognostic factors.
- To evaluate the clinical utility of features beyond metastatic LN count.
Main Methods:
- Comprehensive literature review focusing on GC lymph node staging.
- Analysis of alternative staging systems, sentinel lymph node (SLN) biopsy, lymph node micrometastases (LNMIs), extracapsular extension (ECE), and tumor deposits (TDs).
Main Results:
- The TNM classification has good prognostic performance, but alternative methods (LN ratio, log odds of positive LNs) may offer superior accuracy.
- The clinical impact and pathological analysis of SLN biopsy and LNMIs in GC remain unclear.
- Extracapsular extension and tumor deposits are identified as independent prognostic factors for GC survival.
Conclusions:
- Further research is needed to integrate novel features into GC staging.
- Standardization of alternative lymph node staging systems is crucial for clinical practice.
- Evaluating the impact of ECE and TDs on TNM classification and patient outcomes requires further investigation.
